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Background: The prediction of ﬁbrosis is an essential part of the assessment and man-
agement of patients with chronic liver disease. Non-invasive tests (NITs) have a number 
of advantages over the traditional standard of ﬁbrosis assessment by liver biopsy, includ-
ing safety, cost-eﬀectiveness, and widespread accessibility. 
Objectives: The aim of this study was to determine the accuracy of certain biomarkers 
and transient elastography (TE) alone or in combination to predict the stage of liver ﬁ-
brosis in chronic hepatitis C (CHC). Also, we examined whether the combination of cer-
tain biomarkers and TE could increase the diagnostic accuracy of liver ﬁbrosis assess-
ment.
Patients and Method: A total of 446 patients who were previously diagnosed with CHC 
were included in the study. In the study group, 6 blood-based scores (APRI, Forns, Fib-4, 
Hepascore, FibroTest, and Fibrometer) were calculated, and TE was performed to validate 
the stage of ﬁbrosis, compared with liver biopsy (LB) as the standard. 
Results: Signiﬁcant ﬁbrosis (F ≥ 2) was predicted with an AUROC of 0.727, 0.680, 0.714, 
0.778, 0.688, 0.797, and 0.751 for the APRI, Forns, Fib-4, FibroTest, Hepascore, and Fibro-
meter scores and TE (Fibroscan), respectively. Severe ﬁbrosis (F ≥ 3) was predicted, with 
AUROCs ranging between 0.705 and 0.811 for Hepascore and Fibrometer, respectively. Of 
the biomarkers, Fibrometer had the highest AUROC value in predicting both signiﬁcant 
and severe ﬁbrosis. The combination of APRI or FIB-4 with Fibrometer increased the di-
agnostic accuracy for signiﬁcant ﬁbrosis (from 69.07 to 82.27 for APRI, P = 0.001 and from 
57.74 to 81.33, P = 0.001 for Fib-4). Combining APRI or Fib-4 with TE also increased the 
diagnostic accuracy (from 69.07 to 80.70%, P = 0.001 for APRI and from 57.74 to 81.33%, P = 
0.001 for Fib-4) for signiﬁcant ﬁbrosis. The association that included Fibrotest was also 
reliable for the improvement of diagnostic accuracy. These combinations were more ac-
curate or the assessment of severe ﬁbrosis. 
Conclusions: The synchronous association between a simple, inexpensive score and 
a complex but expensive score or TE increases the diagnostic accuracy of non-invasive 
methods for the assessment of liver ﬁbrosis stage. 
 Implication for health policy/practice/research/medical education:
This article is appropriate for researchers who are interested in articles related to the liver ﬁbrosis and Chronic Hepatitis C. The 
article is also applied for the hematologists, virologists, gastroenterologists, internal specialists, and infectious disease specialists. 
Given the importance of managing chronic liver disease patients, diagnosis of liver ﬁbrosis is very important.
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1. Background
Progressive hepatic ﬁbrosis is a characteristic of chron-
ic liver diseases, and its signiﬁcance derives from the 
evolution toward cirrhosis with subsequent complica-
tions. Therefore, the assessment of ﬁbrosis in chronic 
liver diseases not only is a determinant of the progno-
sis but also establishes the optimal timing of therapy, 
screening, and surveillance strategies and may also pre-
dict the treatment response. Historically, the stage of ﬁ-
brosis has been assessed by liver biopsy, and despite its 
inconveniences, this method remains the standard of 
evaluation. Liver biopsy (LB) also has the advantages of 
suggesting the etiology and assessing potential disease 
cofactors, such as hepatic steatosis, hepatocellular iron, 
and necroinﬂammatory activity. On the other hand, liver 
biopsy is an invasive method that is painful and has a risk 
of bleeding (1). Furthermore, liver biopsy is costly and 
brings into discussion the sampling error (2) and diﬀer-
ences in pathologist interpretation (3). These limitations 
have led to the search for alternative, non-invasive tests 
for ﬁbrosis assessment, including clinical and serum 
biomarker algorithms. The number of serum biomarker 
algorithms for liver ﬁbrosis has increased signiﬁcantly 
over the past decade, and they are beginning to be in-
corporated into routine clinical practice. Biomarkers 
of ﬁbrosis are typically divided into indirect and direct 
markers of ﬁbrogenesis and ﬁbrolysis. Indirect markers 
include simple, routine tests, such as aminotransferases, 
platelet count, and albumin or prothrombin time (4). Di-
rect markers include serum levels of matrix metallopro-
teinases and hyaluronic acid and cytokines, such as tu-
mor necrosis factor-a (TNF-α) and transforming growth 
factor-β (TGF-β), which are more directly involved in the 
molecular pathogenesis of ﬁbrogenesis and ﬁbrolysis 
(5).
In addition to the advantages of noninvasive biomark-
ers, there are some pitfalls that render these algorithms 
imperfect. Many of the models that are used for the as-
sessment of liver ﬁbrosis have good accuracy in deter-
mining advanced ﬁbrosis and cirrhosis, but the main 
challenge remains the determination of mid-levels of 
ﬁbrosis. The same problem also exists for TE. The compo-
nents of scores or algorithms can also contribute to the 
imperfection of these diagnostic methods.  In general, 
models that include direct markers of ﬁbrogenesis (Fi-
brotest, Hepascore, Fibrospect) tend to have higher accu-
racy in predicting signiﬁcant ﬁbrosis than those that are 
based on indirect measures (APRI, Forns, FIB-4), although 
comparative studies have often failed to detect statisti-
cally signiﬁcant diﬀerences. Transient elastography is a 
novel, rapid, noninvasive, and reproducible method for 
measuring liver stiﬀness. Preliminary reports suggest 
that FS accurately predicts hepatic ﬁbrosis in patients 
with chronic hepatitis C.
2. Objectives
The aim of this study was to evaluate the diagnostic per-
formance and reliability of non-invasive serological and 
imagistic methods for the assessment of signiﬁcant and 
severe ﬁbrosis in chronic hepatitis C (CHC) compared to 
liver biopsy. Also, we evaluated the possibility of an in-
crease in diagnostic accuracy when we combined diﬀer-
ent scores or when we added an imagistic method to the 
biomarkers to assess the severity of liver ﬁbrosis.
3. Patients and Method
This study prospectively included 446 consecutive 
patients who were previously diagnosed with CHC and 
underwent liver biopsy at the 3rd Medical Clinic, Cluj-
Napoca, Romania. Chronic hepatitis C infection was de-
ﬁned as the presence of anti-HCV for at least 6 months 
and positivity for HCV RNA.  We excluded patients with 
other etiologies of chronic liver disease, such as hepatitis 
B, autoimmune liver disease, Wilson disease, hemochro-
matosis, α1-antitripsin deﬁciency, and HIV infection; and 
patients with a history of hepatotoxic or steatosis-induc-
ing drug use or alcohol consumption of more than 20 g/
day for women and 30 g/day for men. All patients were 
naïve for antiviral treatment. The study was performed 
in full accordance with the Declaration of Human Rights 
(Helsinki, 1975) and its revisions. Complete, comprehen-
sive, and clear informed consent was obtained from the 
patients. The study was approved by the local ethical 
committee of the Clinical Emergency Hospital “Prof. Dr. 
Octavian Fodor” in Cluj-Napoca. All patients signed prior 
informed consent forms on inclusion into the study.
3.1. Laboratory Investigations
All patients underwent hematological, biochemical, 
and virological examinations on the day of their partici-
pation. In order to exclude biliary obstruction and the 
presence of liver focal lesions, abdominal ultrasonog-
raphy was performed for all patients on inclusion into 
study. A blood sample was obtained after 8 hours of over-
night fasting for routine investigations (aminotrans-
ferases, AST, ALT, fasting plasma glucose, platelet count, 
gamma glutamyl transpeptidase, bilirubin, cholesterol, 
urea, prothrombin time). All assessments were made 
on an automatic analyzer (Konelab 30 I – Thermo Elec-
tron Corp Finland). All patients were infected with HCV 
genotype 1. Serum HCV RNA was measured by PCR (Cobas 
Amplicor HCV 2.0 version, Roche). Serum samples from 
each patient were stored at -70°C for further biochemical 179 Hepat Mon. 2012
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analysis. All biochemical tests and their scores were as-
sessed without knowledge of the liver biopsy results. The 
serum biochemical markers α2 macroglobulin (α2-MG), 
haptoglobin, and apolipoprotein A1 were assessed by 
nephelometry. The following non-invasive markers were 
determined in the study group, per published formulas: 
AST-to-platelet ratio index (APRI) (6) Forns’ index (7), and 
Fib-4 (8). The formulas for the serological scores were:
- APRI = [{AST (IU/l)/ ALT_ULN (IU/l)} × 100]/ platelet 
count (109/L) 
- FiB-4 = [age (y) × AST (IU/L)]/ [platelet count (109/L) × ALT 
(IU/L) 1/2]
- Forns’ Index = 7.811 - 3.131 × ln [platelet count (109/L)] + 
0.781 × ln[GGT(IU/L)] + 3.467 × ln [age (y)] – 0.014 [choles-
terol (mg/dL)] 
The following blood tests were also evaluated: Fi-
brotest® (9), Fibrometer (10), Hepascore® (11), calculat-
ed according to the patented formulas or computed on 
the dedicated websites. 
3.2. Liver Stiﬀness Measurement
Transient elastography (TE) (Fibroscan ©, Echosens, 
Paris, France) (12) was performed on the right liver lobe 
by a well-trained and experienced operator. TE was con-
sidered valid if 10 measurements were obtained with a 
success rate of > 60% and an interquartile range < 30% of 
the median. Patients with invalid scores were excluded 
from the analysis.
3.3. Morphopathological Study
Liver biopsies, obtained under ultrasonographic guid-
ance and stained with  hematoxylin-eosin and Masson’s 
trichrome, were assessed blindly per the METAVIR scor-
ing system (13) by an expert pathologist. According to the 
METAVIR system, ﬁbrosis was staged on a scale from F0 
to F4, as follows: F0: no ﬁbrosis; F1: portal ﬁbrosis, with-
out septa; F2: few septa; F3: many septa without cirrhosis; 
and F4: cirrhosis. F0 and F1 were considered insigniﬁcant 
ﬁbrosis, whereas scores of F2-F4 were considered signiﬁ-
cant ﬁbrosis; F3-F4 was considered severe ﬁbrosis.
3.4. Statistical Analysis
Comparisons between groups were made using stu-
dent’s t-test for continuous variables with normal distri-
bution and χ2 test for categorical variables. Values were 
expressed as mean ± SD. Continuous variables with non-
normal distribution were expressed as median and 25-
75th percentiles, and the diﬀerences were analyzed by 
Mann-Whitney test. Correlations between scores and ﬁ-
brosis stage variables were established using Spearman’s 
rank correlation. Variables that achieved statistical sig-
niﬁcance in the univariate analysis were included in an 
ordinal regression analysis to evaluate the independent 
factors that were associated with signiﬁcant ﬁbrosis. P < 
0.05 was considered statistically signiﬁcant. Binary anal-
ysis was performed using receiver operator characteris-
tic (ROC) curves, separating patients into 2 groups based 
on ﬁbrosis stage (F0-1 vs. F2-4 and F0-2 vs. F3-4). Cutoﬀ val-
ues for each test in the cohort were established, where 
sensitivity and speciﬁcity were maximal. The diagnostic 
value of each test was assessed through the area under 
the ROC (AUROC), and it was also expressed as a percent-
age for the diagnostic accuracy. Standardization of AU-
ROC was performed based on the prevalence of ﬁbrosis 
stages (DANA method) (14). The sensibility (Se), speciﬁc-
ity (Sp), positive predictive value (PPV), negative predic-
tive value (NPV), positive likelihood ratio (PLR) and nega-
tive likelihood ratio (NLR) of the serum biomarkers in 
predicting diﬀerent stages of ﬁbrosis were calculated us-
ing ROC analysis. De Long’s method was used for AUROC 
comparison. The diagnostic value of the combinations of 
diﬀerent scores was assessed using tests for dichotomic 
variables. The agreement between methods was assessed 
using McNemar test for the categorial variables and the 
diagnostic accuracy based on true positive, true nega-
tive, false positive and false negative data. We used Med-
Calc® 9.3.9.0. and SPSS version 15.0 (SPSS Inc. Chicago, IL, 
USA) for the statistical analysis
4. Results
The clinical, biochemical, and histological data are 
summarized in (Table 1). The mean age of the study group 
was 49 year, with a predominance of females (61.59%). 
The median length of the liver biopsy samples was 11.45 
mm, with a mean number of portal spaces of 13.58. No 
sample had fewer than 6 portal spaces. The ﬁbrosis stage 
distribution was as follows: F0, n = 30 (6.72%); F1, n = 133 
(28.82%); F2, n = 161 (36.09%); F3, n = 81 (18.16%); and F4, n = 
41 (9.19%). The output of each marker was compared with 
the ﬁbrosis stage, divided into 2 groups, depending on 
signiﬁcant and severe ﬁbrosis. We compared the diﬀer-
ences in scores between the patients with signiﬁcant ﬁ-
brosis and mild ﬁbrosis and between those with severe 
ﬁbrosis and mild-moderate ﬁbrosis, from which we ob-
tained the corresponding AUROCs (Table 2). Liver stiﬀness 
ranged from 3 to 27 kPa (median 7.1 [5.450 - 10.125]). The 
most discriminant cutoﬀ values were determined from 
the distribution of stiﬀness values according to ﬁbrosis 
stage and ROC curves: 7.9 for F ≥ 2 and 9 for F ≥ 3. In pa-
tients with stiﬀness values greater than 7.9 kPa, the like-
lihood of signiﬁcant ﬁbrosis was 90.3% (positive predic-
tive value). The AUROC for each test for the diagnosis of 
signiﬁcant ﬁbrosis ranged between 0.680 for Forns score 
and 0.797 for Fibrometer (Table 1). For the discrimination 
of severe ﬁbrosis, AUROCs of non-invasive tests ranged 
between 0.737 for Forns score and 0.811 for Fibrometer 
(Table 2). The comparison of ROC curves demonstrated 
slight diﬀerences in diagnostic performance between 
indirect and direct biomarker tests and also for the TE. 
In order to improve the diagnostic performance, a com-
bination of 2 or 3 methods was tested. Because APRI and 
Fib-4 were the simple non-invasive tests that appeared 
to have better diagnostic accuracy for signiﬁcant and 
severe ﬁbrosis, they were chosen to form combinations 
with complex patented formulas or TE. As Fibrometer 180 Hepat Mon. 2012
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Table 1. Demographic, Laboratory, and Histological Features of Patients With Chronic Hepatitis C
Patients (n = 446)
Gender, No. (%), (median)
Males
Females
170 (38.1)
276 (61.59)
Age, y, No. (%) 49 (40 – 56)
BMI, kg/m2, (median) 26.56 (23.66 – 29.74)
Prothrombin time, s, (median) 99 (89.00 – 108.30)
Total cholesterol, mg/dL, (median)  192.00 (167.00 – 220.50)
Bilirubin, mg/dL, (median)  0.70 (0.54 – 0.89)
AST, IU/L, (median)  50.00 (34.00 – 73.50)
ALT, IU/L, (median)  76.00 (51.00 – 117.50)
GGT, IU/L, (median)  52.00 (34.00 – 88.00)
Urea, mg/dL, (median)  33.00 (27.00 – 41.00)
Platelet count, Giga/L, (median)  210.00 (169.00 – 247.25)
Length of biopsy, mm, mean ± SD, (median)  11.45 ± 0.68
Portal tracts, No., mean ± SD, (median) 13.58 ± 4.74
Liver ﬁbrosis according to METAVIR , No. (%)
F0
F1
F2
F3
F4
30 (6.72)
133 (28.82)
161 (36.09)
81 (18.16)
41 (9.19)
and Fibotest had the best accuracy with regard to direct 
complex scores, they formed paired combinations with 
APRI and Fib-4. The diagnostic accuracy for signiﬁcant ﬁ-
brosis increased signiﬁcantly when Fibrometer was add-
ed to APRI (from 69.03 to 82.27, P = 0.001) and Fib-4 (from 
57.74 to 81.33, P = 0.001) (Table 3). Another useful combina-
tion for the improvement of signiﬁcant ﬁbosis was the 
association of APRI with Fibrotest (diagnostic accuracy 
increased from 69.03 to 80.70) and Fib-4 with Fibrotest 
(accuracy increased from 57.74 to 78.44). The association 
Table 2. The Performance of Non-Invasive Serological Tests and TE Expressed by AUROC in Discriminating Signiﬁcant and Sever Fibrosis (F0-1 vs. F2-4)
Score AUC a 95% CI Cut-oﬀ Se a Sp a PPV a NPV a PLR a NLR a Accuracy
Discriminating Signiﬁcant Fibrosis
APRI a 0.727 0.666 to 0.783 0.44 71.92 66.67 77.2 60.2 2.16 0.42 69.03
Forns 0.680 0.616 to 0.739 4.47 79.86 49.45 41.4 60.8 1.58 0.41 67.23
Fib-4 0.714 0.652 to 0.771 1.26 64.38 75.27 80.3 57.4 2.60 0.47 57.74
Hepascore 0.688 0.618 to 0.751 0.34 57.25 72.13 82.3 42.7 2.05 0.59 61.3
Fibro meter 0.797 0.722 to 0.860 0.59 68.75 80.85 88.0 55.9 3.59 0.39 72.72
Fibro Test 0.778 0.722 to 0.828 0.34 64.91 79.52 86.7 52.4 3.17 0.44 73.33
TE 0.751 0.681 to 0.813 7.90 53.72 87.50 90.3 46.7 4.30 0.50 64.55
Discriminating Sever Fibrosis
APRI 0.741 0.681 to 0.796 1.69 61.40 77.47 46.1 86.5 2.73 0.50 72.38
Forns 0.737 0.676 to 0.792 7.3 85.71 48.60 34.3 91.6 1.67 0.29 57.02
FIB-4 0.767 0.708 to 0.819 3.74 63.16 80.77 50.7 87.5 3.28 0.46 76.15
Hepascore 0.705 0.636 to 0.767 0.61 60.66 73.19 50.0 80.8 2.26 0.54 68.84
Fibro meter 0.811 0.737 to 0.871 0.76 80.5 72.5 54.1 90.2 2.93 0.27 71.32
Fibro Test 0.782 0.726 to 0.831 0.54 82.89 63.48 49.2 89.7 2.27 0.27 70.07
TE 0.809 0.743 to 0.864 9.00 69.57 84.73 71.5 88.8 4.56 0.36 79.66
a Abbreviations: APRI, aspartate aminotransferase to platelet ratio index; AUC, area under curve; NLR, negative likelihood ratio; NPV, negative predictive 
value; PLR, positive likelihood ratio; PPV, positive predictive value; Se, sensitivity; Sp, speciﬁcity; TE, transient elastography181 Hepat Mon. 2012
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of TE to the simple scores also improved diagnostic ac-
curacy for the prediction of F2. The best diagnostic value 
was obtained with the combination of APRI and Fibrom-
eter for the discrimination of signiﬁcant ﬁbrosis. 
Severe ﬁbrosis was also evaluated through simple 
scores combined with Fibrometer; we noted a signiﬁcant 
increase in the diagnostic accuracy for APRI associated 
with Fibrometer (from 72.38 to 82.75, P = 0.006) and for 
Fib-4 with Fibrometer (from 76.15 to 89.02, P = 0.001). 
The algorithm including Fibrotest resulted in nearly the 
same beneﬁt for the diagnostic of severe ﬁbrosis, not 
only in combination with APRI (accuracy increased from 
72.38 to 81.18) but also added to Fib-4 (accuracy increased 
from 76.15 to 83.65). The combination with TE was also 
eﬀective in increasing the diagnostic accuracy of severe 
ﬁbrosis, reaching statistical signiﬁcance (APRI+TE, accu-
racy increased from 72.38 to 85.71, and Fib-4+TE from 76.15 
to 87.83) (Table 3). The best diagnostic value was obtained 
with the combination of Fib-4 and Fibrometer for the 
discrimination of severe ﬁbrosis. The combination of the 
two indirect scores, APRI and Fib-4, did not signiﬁcantly 
increase the diagnostic accuracy for signiﬁcant or severe 
ﬁbrosis (P = 0.55, respectively 0.21). We also evaluated the 
combination of three markers (two simple scores with 
Fibrometer, Fibrotest, or TE), but the diagnostic accuracy 
did not increase compared to former associations (APRI 
plus Fibrometer or APRI plus TE; Fib-4 plus Fibrometer 
or Fib-4 plus TE). Nevertheless, the association of three 
scores, including one of the complex scores (Fibrometer, 
Fibrotest or TE), and two simple scores had a signiﬁcantly 
higher diagnostic accuracy compared to the combina-
tion of the two simple indirect tests (Table 3). APRI and 
Fibrometer agreed on the discrimination of signiﬁcant 
ﬁbrosis in 70% of patients. The concordant cases of APRI 
and Fibrometer were conﬁrmed by LB in 82%. Among 18% 
of discordant cases, 17% of cases were classiﬁed as F < 2 
by APRI and Fibrometer and F ≥ 2 by LB, and 1% of cases 
were classiﬁed as F ≥ 2 by APRI and Fibrometer and F < 2 
by LB. When Fib-4 and Fibrometer agreed on the discrimi-
nation of signiﬁcant ﬁbrosis, which was the case in 78% of 
the patients, the concordance with the LB examination 
was 81%. Of the 19% of discordant cases, 15% was classiﬁed 
as < F2 by blood test and F ≥ 2 by LB and 4% was classi-
ﬁed as F ≥ 2 by blood test and F < 2 by LB. When TE was 
Score Se a Sp a PPV a NPV a Accuracy P value
Discriminating Signiﬁcant Fibrosis
APRI a 71.92 66.67 77.2 60.2 69.03
APRI + Fibrometer 
APRI + FibroTest
APRI+TE a
79.24
79.24
72.91
88.46
88.46
100
93.33
91.30
100
67.64
64.44
56.66
82.27
80.70
79.68
0.001
0.001
0.001
Fib-4 64.38 75.27 80.3 57.4 57.74
Fib-4 + Fibrometer
Fib-4 + FibroTest
Fib-4 + TE
75.51
75.64
47.61
92.30
84.21
100
94.87
90.76
100
66.66
62.74
56
81.33
78.44
68.57
0.001
0.001
0.02
APRI + Fib-4 71.42 73.29 82.56 59.09 72.08 0.36(/APRI)
APRI + Fib-4+Fibrometer
APRI + Fib-4+FibroTest
APRI+Fib-4 + TE
80.00
73.97
73.80
95.00
86.60
100
97.29
93.65
100
67.85
65.00
57.69
84.61
82.52
80.70
0.001/NS b
0.001 /NS c
0.001/NS d
Discriminating Severe Fibrosis
APRI 61.40 77.47 46.1 86.5 72.38
APRI+Fibrometer
APRI+FibroTest
APRI+TE
78.26
89.65
73.3
84.37
77.77
81.71
64.28
61.90
61.11
91.52
94.91
92.59
82.75
81.18
85.71
0.006
0.02
0.001
Fib-4 63.16 80.77 50.7 87.5 76.15
Fib-4+Fibrometer
Fib-4+FibroTest
Fib-4+TE
84.21
89.28
75.00
90.47
81.57
91.37
72.72
64.10
70.58
95.00
95.38
92.98
89.02
83.65
87.83
0.001
0.01
0.001
APRI+Fib-4 64.58 81.87 51.66 88.51 75.88
APRI+Fib-4+Fibrometer
APRI+Fib-4+FibroTest
APRI+Fib-4+TE
84.21
88.46
62.5
91.07
83.18
100
76.19
67.64
100
94.44
94.91
58.62
89.33
84.94
85.51
0.001/NS b
0.003/NS c
0.001/NS d
a Abbreviations: APRI, aspartate aminotransferase to platelet ratio index; PPV, positive predictive value; NPV, negative predictive value; Se, sensitivity; Sp, 
speciﬁcity; TE, transient elastography
b P APRI+ Fib-4/P APRI + Fibro meter
c P APRI+ Fib-4/ P APRI + Fibro Test
d P APRI+ Fib-4/P APRI + TE 
Table 3. Comparison of Diagnostic Accuracy for the Combination of Non-Invasive Tests in Discriminating Signiﬁcant and Severe Fibrosis (F0-1 vs. F2-4)182 Hepat Mon. 2012
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included in the algorithm, we noted an agreement on 
signiﬁcant ﬁbrosis of 74.5% between APRI and TE, with 
a concordance of 86% with LB. In the 14% in whom they 
were not concordant, 12% of cases were classiﬁed as F < 
2 by Fib-4 and Fibrometer and F ≥ 3 by LB, and 2% of the 
cases were classiﬁed as F ≥ 2 by blood test and F < 3 by LB. 
The analysis for the discrimination of severe ﬁbrosis, in-
corporating APRI or Fib-4 with Fibrometer, revealed simi-
lar results with the same tests applied for the discrimina-
tion of signiﬁcant ﬁbrosis. 
5. Discussion
Biomarkers and TE have been recently developed as al-
ternatives to liver biopsy for the staging of liver ﬁbrosis 
(15). Retrospective studies (16-18) have compared several 
of these markers to liver biopsy. The real indicator of 
liver disease status is a histological analysis of the entire 
liver, but it is impossible to obtain this in practice; hence, 
liver biopsy remains “the best but not the gold standard” 
(19). Many non-invasive methods have been proposed 
for the assessment of liver ﬁbrosis. There are mainly 
two ways to approach the assessment of liver ﬁbrosis: 
using a single test or a combination of diﬀerent NITs in 
so-called “decision-making algorithms”: SAFE (Sequen-
tial Algorithm for Fibrosis Evaluation) or BA (Bordeaux 
Algorithm) (20). As the use of serum biomarkers and TE 
as individual methods is not the gold standard, in order 
to increase the diagnostic performance of non-invasive 
markers of liver ﬁbrosis, researchers have tried to com-
bine them in algorithms. Stepwise combination of APRI 
and Fibro Test improved the diagnostic performance in 
CHC, with a consequent decrease for the need of liver bi-
opsy by 50% to 70% (21). Another study tried to validate 
SAFE, which detects signiﬁcant ﬁbrosis and cirrhosis by 
combining the AST-to-platelet ratio index and Fibrotest-
Fibrosure, and concluded that SAFE is a rational and 
validated method for staging liver ﬁbrosis in hepatitis C 
(22). Castera et al. compared the diagnostic accuracy of 2 
algorithms (SAFE and a combination between FT and TE 
based on agreement between these tests) and concluded 
that both algorithms are eﬀective for non-invasive stag-
ing of liver ﬁbrosis in CHC (23).
Our study evaluated the diagnostic performance of 
APRI, Forns, Fib-4, Hepascore, FibroTest, Fibrometer, and 
TE for the staging of ﬁbrosis in CHC, as compared to LB. 
The performance of these scores was similar, with slight-
ly insigniﬁcant diﬀerences, as reported in other studies 
(24). The AUROC of each studied test was comparable 
to those reported in the original publications (6-12). For 
Fibrotest®, Hepascore®, Fibrometer®, and TE, the diag-
nostic performance was almost similar to those reported 
in meta-analyses (25-27). Fibrometer performed better 
than simple tests in discriminating signiﬁcant ﬁbrosis 
and severe ﬁbrosis. We tried to increase the diagnos-
tic accuracy using combinations of simple serological 
markers with complex biomarkers or with TE. The asso-
ciations were made on the basis of cost and accessibil-
ity. The possible combinations of markers were derived 
from multiple regression of the AUROCs.
Our results suggested that an algorithm combining Fi-
brometer, FibroTest, or TE with simple tests, such as APRI 
and or Fib-4, could improve the accuracy for signiﬁcant 
and severe ﬁbrosis and consequently decrease the need 
for biopsy. These combinations could be used reliably for 
the evaluation of ﬁbrosis in HCV-infected patients, and 
this could avoid LB examination in most patients with 
CHC. The diagnostic performance of TE, FibroTest, and 
APRI based on AUROC values has been analyzed in many 
studies (15, 25, 28, 29). These studies did not show sig-
niﬁcant diﬀerences, although TE and FT usually tended 
to perform slightly better than APRI, but there are some 
studies that have suggested that FT provides a more ac-
curate estimation of ﬁbrosis in CHC than APRI (29). Fi-
brotest was included in combinations of scores in order 
to increase the diagnostic accuracy, and the number of 
well-classiﬁed patients was 76% in combination with Fi-
brometer and Hepascore and 80% with APRI (30). Anoth-
er study reported a concordance of the combination of 
Fibotest, TE, and LB of 84% (31). On the other hand, there 
are few studies that have included Fibrometer in a com-
bined analysis of diagnostic performance.
New ﬁbrosis indexes combining Fibrometer and Fi-
broscan have been developed for the diagnosis of clini-
cally signiﬁcant ﬁbrosis (CSF-index) or severe ﬁbrosis (SF-
index). Their association provided a new ﬁbrosis stage 
classiﬁcation (CSF/SF classiﬁcation): F0/1, F1/2, F2 ± 1, F2/3, 
F3 ± 1, and F4. This classiﬁcation had high diagnostic accu-
racy (85.8% well-classiﬁed patients), signiﬁcantly higher 
than the diagnostic accuracies of Fibrometer, Fibroscan, 
and Fibrotest (32). Another study combined synchro-
nous Fibrometer and TE, with a diagnostic accuracy of 
91.9% for liver ﬁbrosis staging, signiﬁcantly higher than 
Fibrometer or TE alone, and with a higher percentage of 
avoided liver biopsies than previously published SAFE 
and Bordeaux algorithms (33). Considering that Fibrom-
eter performed well in our study group, we analyzed 
whether combinations that included this test could in-
crease the diagnostic accuracy. The results revealed that 
adding Fibrometer to a simple inexpensive test would 
increase the performance of the biomarkers for discrimi-
nating signiﬁcant and severe ﬁbrosis. The combination 
of Fibrometer with APRI could be reliably used for the 
evaluation of ﬁbrosis and consequently avoid LB, as dem-
onstrated by the percentage by which the 2 tests agreed 
(90%) and were concordant with LB. 
A similar observation is also valid for the combination 
of Fib-4 plus Fibrometer for the discrimination of sig-
niﬁcant ﬁbrosis. With regard to severe and signiﬁcant 
ﬁbrosis, we found that not only was the combination of 
simple scores with Fibrometer useful for the diagnostic 
performance, the combination of APRI or Fib-4 with TE 
also increased the accuracy of the non-invasive methods. 
APRI and TE agreed on the discrimination of severe ﬁbro-
sis in 74.5%, consistent with the results of liver biopsy in 
85.7% of cases. In a similar analysis, which studied the 
performance of TE and FibroTest, Castera et al. obtained a 183 Hepat Mon. 2012
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concordance of 84% between these two methods and LB 
for signiﬁcant ﬁbrosis and 95% for severe ﬁbrosis (31). A 
very recently published study, comparing 9 of the well-
known blood tests and TE, demonstrated a rate of 78% of 
well-classiﬁed patients with regard to signiﬁcant ﬁbrosis 
for the combination of APRI with Fibrometer. The associ-
ation of Hepascore or FibroTest with APRI resulted in 80% 
well-classiﬁed patients; the percentage of theoretically 
avoided LB ranges from 58% to 62% for these tests (30). 
When the study of non-invasive methods for assessment 
of liver biopsy becomes a concern, another important is-
sue is the cost of diﬀerent diagnostic methods. There are 
some studies that assessed the cost-eﬀectiveness of non-
invasive testing strategies in comparison with liver biop-
sy (34). The authors reported cost savings of $770/person 
with the Fibrotest and $1120 with Fibroscan compared to 
liver biopsy, underlining the accesibility of non-invasive 
methods. However, the authors also reported that there 
is a decrease in diagnostic accuracy of 14% with Fibrotest 
and of 18% with Fibroscan compared to LB. Our study has 
some limitations. One is the length of the LB sample. In 
order to avoid misdiagnosis and the errors of interpreta-
tion, only biopsy specimens with more than 6 intact por-
tal tracts were eligible for evaluation (35). The diagnostic 
performance of TE also might have been underestimat-
ed. TE may provide a more accurate and reproducible 
picture of ﬁbrosis stage than LB examination in patients 
with cirrhosis. Even if it has many advantages—it is pain-
less, rapid, and easy to perform—unfortunately, it has 
some limitations, especially in the case of obesity and as-
cites. On the other hand, morphologically speaking, the 
increased grade of steatosis might be responsible for the 
false positive results of increased liver stiﬀness (12).
In summary, the analysis of the diagnostic performance 
of  biomarkers for the assessment of  liver ﬁbrosis and 
transient elastography show that when isolated, these 
methods perform similarly with slightly diﬀerences, but 
a synchronous combination of a simple, inexpensive 
blood test that incorporates routine biochemical deter-
minations with Fibrometer, FibroTest, or TE eﬀectively 
increases the diagnostic performance of NIT. Improving 
the diagnosis accuracy, this type of combination could 
decrease the need for biopsy, but further studies are 
needed to assess the optimal combinations, based on 
cost-beneﬁt.  Although the combination of three tests 
had signiﬁcant accuracy, this small increase does not jus-
tify the cost of the investigations.
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